PhanankosiMoyo Moyo

Dr. PhanankosiMoyo Moyo

University of Pretoria, Pretoria, South Africa
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
JRJanette Reader
Janette Reader
MWMariëtte E. van der Watt
Mariëtte E. van der Watt
DTDale Taylor
Dale Taylor
CMClaire Le Manach
Claire Le Manach
NMNimisha Mittal
Nimisha Mittal
LBLyn-Marie Birkholtz
Lyn-Marie Birkholtz
Chemical matter is needed to target the divergent biology associated with the different life cycle stages of Plasmodium. Here, we report the parallel de novo screening of the Medicines for Malaria Venture (MMV) Pandemic Response Box against Plasmodium asexual and liver stage parasites, stage IV/V gametocytes, gametes, oocysts and as endectocides. Unique chemotypes were identified with both multistage activity or stage-specific activity, including structurally diverse gametocyte-targeted compounds with potent transmission-blocking activity, such as the JmjC inhibitor ML324 and the antitubercular clinical candidate SQ109. Mechanistic investigations prove that ML324 prevents histone demethylation, resulting in aberrant gene expression and death in gametocytes. Moreover, the selection of parasites resistant to SQ109 implicates the druggable V-type H+-ATPase for the reduced sensitivity. Our data therefore provides an expansive dataset of compounds that could be redirected for antimalarial development and also point towards proteins that can be targeted in multiple parasite life cycle stages.

8 March 2019 in Malaria Journal
Verified
Journal Article
Open access
PDF file
PMPhanankosiMoyo Moyo
PhanankosiMoyo Moyo
PKPhaladi Kunyane
Phaladi Kunyane
MSMamoalosi A. Selepe
Mamoalosi A. Selepe
JEJacobus N. Eloff
Jacobus N. Eloff
JNJandeli Niemand
Jandeli Niemand
LBLyn-Marie Birkholtz
Lyn-Marie Birkholtz
Optimal adoption of the malaria transmission-blocking strategy is currently limited by lack of safe and efficacious drugs. This has sparked the exploration of different sources of drugs in search of transmission-blocking agents. While plant species have been extensively investigated in search of malaria chemotherapeutic agents, comparatively less effort has been channelled towards exploring them in search of transmission-blocking drugs. Artemisia afra (Asteraceae), a prominent feature of South African folk medicine, is used for the treatment of a number of diseases, including malaria. In search of transmission-blocking compounds aimed against Plasmodium parasites, the current study endeavoured to isolate and identify gametocytocidal compounds from A. afra. A bioassay-guided isolation approach was adopted wherein a combination of solvent–solvent partitioning and gravity column chromatography was used. Collected fractions were continuously screened in vitro for their ability to inhibit the viability of primarily late-stage gametocytes of Plasmodium falciparum (NF54 strain), using a parasite lactate dehydrogenase assay. Chemical structures of isolated compounds were elucidated using UPLC-MS/MS and NMR data analysis. Two guaianolide sesquiterpene lactones, 1α,4α-dihydroxybishopsolicepolide and yomogiartemin, were isolated and shown to be active (IC50 < 10 μg/ml; ~ 10 μM) against both gametocytes and intra-erythrocytic asexual P. falciparum parasites. Interestingly, 1α,4α-dihydroxybishopsolicepolide was significantly more potent against late-stage gametocytes than to early-stage gametocytes and intra-erythrocytic asexual P. falciparum parasites. Additionally, both isolated compounds were not overly cytotoxic against HepG2 cells in vitro. This study provides the first instance of isolated compounds from A. afra against P. falciparum gametocytes as a starting point for further investigations on more plant species in search of transmission-blocking compounds.

1 June 2016 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
PMPhanankosiMoyo Moyo
PhanankosiMoyo Moyo
MBM.E. Botha
M.E. Botha
SNS. Nondaba
S. Nondaba
JNJandeli Niemand
Jandeli Niemand
VMVinesh Maharaj
Vinesh Maharaj
LBLyn-Marie Birkholtz
Lyn-Marie Birkholtz


17 September 2020 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
PMPhanankosiMoyo Moyo
PhanankosiMoyo Moyo
GMGrace Mugumbate
Grace Mugumbate
JEJacobus Eloff
Jacobus Eloff
ALAbraham I. Louw
Abraham I. Louw
VMVinesh Maharaj
Vinesh Maharaj
LBLyn-Marie Birkholtz
Lyn-Marie Birkholtz
The ability to block human-to-mosquito and mosquito-to-human transmission of Plasmodium parasites is fundamental to accomplish the ambitious goal of malaria elimination. The WHO currently recommends only primaquine as a transmission-blocking drug but its use is severely restricted by toxicity in some populations. New, safe and clinically effective transmission-blocking drugs therefore need to be discovered. While natural products have been extensively investigated for the development of chemotherapeutic antimalarial agents, their potential use as transmission-blocking drugs is comparatively poorly explored. Here, we provide a comprehensive summary of the activities of natural products (and their derivatives) of plant and microbial origins against sexual stages of Plasmodium parasites and the Anopheles mosquito vector. We identify the prevailing challenges and opportunities and suggest how these can be mitigated and/or exploited in an endeavor to expedite transmission-blocking drug discovery efforts from natural products.

1 August 2020 in International Journal for Parasitology: Drugs and Drug Resistance
Verified
Journal Article
Open access
PMPhanankosiMoyo Moyo
PhanankosiMoyo Moyo
WSWilliam Shamburger
William Shamburger
MWMariëtte E. van der Watt
Mariëtte E. van der Watt
JRJanette Reader
Janette Reader
ASAna Carolina C. de Sousa
Ana Carolina C. de Sousa
LBLyn-Marie Birkholtz
Lyn-Marie Birkholtz
The discovery and development of multistage antimalarial drugs targeting intra-erythrocytic asexual and sexual Plasmodium falciparum parasites is of utmost importance to achieve the ambitious goal of malaria elimination. Here, we report the validation of naphthylisoquinoline (NIQ) alkaloids and their synthetic analogues as multistage active antimalarial drug candidates. A total of 30 compounds were tested, of which 17 exhibited IC50 values 10. The tested compounds showed activity in vitro against both early- and late-stage P. falciparum gametocytes while blocking male gamete formation (>70% inhibition of exflagellation at 2 μM). Additionally, five selected compounds were found to have good solubility (≥170 μM in PBS at pH 6.5), while metabolic stability towards human, mouse, and rat microsomes ranged from >90% to >7% after 30 min. Dioncophylline C (2a) emerged as a front runner from the study, displaying activity against both asexual parasites and gametocytes, a lack of cross-resistance to chloroquine, good solubility, and microsomal stability. Overall, this is the first report on the multistage activity of NIQs and their synthetic analogues including gametocytocidal and gametocidal effects induced by this class of compounds.